infectious disease

Scientists continue to ring alarm bells about the risks associated with the continued misuse of antimicrobials and advocate for innovative treatments, improved surveillance, and greater public health education.

The history of antibody research has led to modern immunotherapy treatments for infectious diseases.

LIVE October 26th, 2021 at 11:00 AM ET
Experts will discuss recent advances in screening strategies to more efficiently identify therapeutic candidates for infectious diseases such as schistosomiasis and COVID-19.

Vaccine development for infectious diseases gives rise to new vaccine approaches and accelerated development and approval timelines.

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.

From microgravity to radiation, space wreaks havoc on astronauts’ immune systems, potentially putting them at risk of infection from microbes onboard.

A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.

Infectious diseases alter the traditional vaccine pipeline and spawn new approaches to antibody research and vaccine development.

To be clear, any adverse event is always one too many. But in the real world, these things happen and often through no intrinsic fault of the therapeutic intervention

Oral ibrexafungerp shows positive results in Phase 3 study against difficult fungal infections